OTC:SGIOY

ViiV Healthcare Announces First Phase II HIV Prevention Study Results for Investigational Long-acting Injectable Cabotegravir

LONDON, Feb. 25, 2016 /PRNewswire/ -- ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the 41 week phase IIa ECLAIR study, which evaluated the safety, tolerability, dosing and sat...

2016-02-25 01:34 3097

ViiV Healthcare Announces Phase II Study Results for First Two Drug, Long-acting Injectable Regimen for HIV-1 Treatment

LONDON, Feb. 24, 2016 /PRNewswire/ -- ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the LATTE-2 study at the Conference on Retroviruses and Opportunistic Infections (CROI) inBo...

2016-02-24 04:03 3232

Week's Top Stories